Integer Holdings

ITGR · NYSE

$126.70−$0.05 (−0.04%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $126.75

ITGR analyst rating

HoldConsensus of 9 analysts over the last 12 months. 22% rate it a buy.

Strong buy0
Buy2
Hold7
Underperform0
Sell0

12-month price target · 9 analysts

Average $122.57 (−3.3% downside)

Low: $98.98
Now: $126.70
High: $133.35

Upgrades and downgrades

The latest rating actions, newest first

ITGR analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Benchmark	Aug 14, 2026	Downgrade	Buy → Hold	—	53%
Oppenheimer	Aug 4, 2026	Downgrade	Outperform → Perform	—	44%
Truist Securities	Aug 4, 2026	Downgrade	Buy → Hold	$110.00 → $127.00	50%
Wells Fargo	Aug 4, 2026	Maintains	Equal-Weight	$84.00 → $127.00	19%
Freedom Capital Markets	Aug 4, 2026	Downgrade	Buy → Hold	—	40%
Keybanc	Aug 3, 2026	Downgrade	Overweight → Sector Weight	—	56%
Freedom Capital Markets	Jul 22, 2026	Initiates	Buy	$112.00	40%
Truist Securities	Jul 16, 2026	Maintains	Buy	$97.00 → $110.00	50%
Citigroup	Jul 8, 2026	Maintains	Neutral	$92.00 → $96.00	60%
Citigroup	May 28, 2026	Maintains	Neutral	$89.00 → $92.00	60%

The case for and against

Updated Oct 14, 2026

Bull case

Integer Holdings is supported by a durable franchise that still posted a Q1 top- and bottom-line beat, with sales of $440M, +1.3% y/y organic, and adjusted EPS of $1.20, while both C&V at $262M and Cardiac & Neuro at $168M outperformed expectations. Although gross margin of 24.9% and adjusted operating margin of 7.2% missed estimates, management’s commentary that core EP demand remains strong and growing in the high-teens suggests the recent forecast reset reflects stabilization rather than structural weakness. The lowered full-year guidance may temper near-term optimism, but the strategic review amid heightened inbound interest and the company’s attractive valuation reinforce the positive fundamental outlook.

Bear case

Integer Holdings is facing a weaker fundamental backdrop as 2Q26 revenue fell 2.6% year over year to $464.1 million and adjusted EPS slipped to $1.60 from $1.65, despite still beating estimates. Management also cut full-year 2026 guidance across revenue, adjusted operating income, and adjusted EPS, citing customer forecast updates and market dynamics, which signals softer near-term demand and margin pressure. The pending KKR acquisition, the absence of forward guidance or a second-quarter earnings call, and exposure to regulatory, competitive, and liquidity risks reinforce a cautious stance despite modest CRM&N growth.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.